Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 100

1.

CoDE-seq, an augmented whole-exome sequencing, enables the accurate detection of CNVs and mutations in Mendelian obesity and intellectual disability.

Montagne L, Derhourhi M, Piton A, Toussaint B, Durand E, Vaillant E, Thuillier D, Gaget S, De Graeve F, Rabearivelo I, Lansiaux A, Lenne B, Sukno S, Desailloud R, Cnop M, Nicolescu R, Cohen L, Zagury JF, Amouyal M, Weill J, Muller J, Sand O, Delobel B, Froguel P, Bonnefond A.

Mol Metab. 2018 Jul;13:1-9. doi: 10.1016/j.molmet.2018.05.005. Epub 2018 May 16.

2.

Phenotypical characterization of peanut allergic children with differences in cross-allergy to tree nuts and other legumes.

Cousin M, Verdun S, Seynave M, Vilain AC, Lansiaux A, Decoster A, Sauvage C.

Pediatr Allergy Immunol. 2017 May;28(3):245-250. doi: 10.1111/pai.12698. Epub 2017 Mar 6.

PMID:
28140482
3.

Human epidermal growth factor receptor 3 in head and neck squamous cell carcinomas.

Rysman B, Mouawad F, Gros A, Lansiaux A, Chevalier D, Meignan S.

Head Neck. 2016 Apr;38 Suppl 1:E2412-8. doi: 10.1002/hed.24367. Epub 2016 Feb 2. Review.

PMID:
26835877
4.

Synthesis and biological activity of ferrocenyl indeno[1,2-c]isoquinolines as topoisomerase II inhibitors.

Wambang N, Schifano-Faux N, Aillerie A, Baldeyrou B, Jacquet C, Bal-Mahieu C, Bousquet T, Pellegrini S, Ndifon PT, Meignan S, Goossens JF, Lansiaux A, Pélinski L.

Bioorg Med Chem. 2016 Feb 15;24(4):651-60. doi: 10.1016/j.bmc.2015.12.033. Epub 2015 Dec 18.

PMID:
26740155
5.

Synergistic Effect of SN-38 in Combination with Cetuximab on Angiogenesis and Cancer Cell Invasion.

Pham MH, Delestre L, Dewitte A, Wattez N, Lepretre F, Lansiaux A.

Anticancer Res. 2015 Nov;35(11):5983-91.

PMID:
26504021
6.

Synthesis, antitumor activity, and mechanism of action of benzo[b]chromeno[6,5-g][1,8]naphthyridin-7-one analogs of acronycine.

Tian W, Yougnia R, Depauw S, Lansiaux A, David-Cordonnier MH, Pfeiffer B, Kraus-Berthier L, Léonce S, Pierré A, Dufat H, Michel S.

J Med Chem. 2014 Dec 26;57(24):10329-42. doi: 10.1021/jm500927d. Epub 2014 Dec 9.

PMID:
25360689
7.

Activity of the polyamine-vectorized anti-cancer drug F14512 against pediatric glioma and neuroblastoma cell lines.

Leblond P, Boulet E, Bal-Mahieu C, Pillon A, Kruczynski A, Guilbaud N, Bailly C, Sarrazin T, Lartigau E, Lansiaux A, Meignan S.

Invest New Drugs. 2014 Oct;32(5):883-92. doi: 10.1007/s10637-014-0132-3. Epub 2014 Jul 11.

PMID:
25008900
8.

The antitumor drug F14512 enhances cisplatin and ionizing radiation effects in head and neck squamous carcinoma cell lines.

Mouawad F, Gros A, Rysman B, Bal-Mahieu C, Bertheau C, Horn S, Sarrazin T, Lartigau E, Chevalier D, Bailly C, Lansiaux A, Meignan S.

Oral Oncol. 2014 Feb;50(2):113-9. doi: 10.1016/j.oraloncology.2013.11.003. Epub 2013 Nov 26.

PMID:
24290982
9.

Low level of baseline circulating VEGF-A is associated with better outcome in patients with vascular sarcomas receiving sorafenib: an ancillary study from a phase II trial.

Penel N, Ray-Coquard I, Bal-Mahieu C, Chevreau C, Le Cesne A, Italiano A, Bompas E, Clisant S, Baldeyrou B, Lansiaux A, Robin YM, Bay JO, Piperno-Neumann S, Blay JY, Fournier C.

Target Oncol. 2014 Sep;9(3):273-7. doi: 10.1007/s11523-013-0299-0. Epub 2013 Nov 12.

PMID:
24218035
10.

Cilengitide targets pediatric glioma and neuroblastoma cells through cell detachment and anoikis induction.

Leblond P, Dewitte A, Le Tinier F, Bal-Mahieu C, Baroncini M, Sarrazin T, Lartigau E, Lansiaux A, Meignan S.

Anticancer Drugs. 2013 Sep;24(8):818-25. doi: 10.1097/CAD.0b013e328362edc5.

PMID:
23728220
11.

Synthesis, antiproliferative activity and tubulin targeting effect of acridinone and dioxophenothiazine derivatives.

Verones V, Flouquet N, Lecoeur M, Lemoine A, Farce A, Baldeyrou B, Mahieu C, Wattez N, Lansiaux A, Goossens JF, Berthelot P, Lebegue N.

Eur J Med Chem. 2013 Jan;59:39-47. doi: 10.1016/j.ejmech.2012.10.051. Epub 2012 Nov 8.

PMID:
23202849
12.

New selective carbonic anhydrase IX inhibitors: synthesis and pharmacological evaluation of diarylpyrazole-benzenesulfonamides.

Rogez-Florent T, Meignan S, Foulon C, Six P, Gros A, Bal-Mahieu C, Supuran CT, Scozzafava A, Frédérick R, Masereel B, Depreux P, Lansiaux A, Goossens JF, Gluszok S, Goossens L.

Bioorg Med Chem. 2013 Mar 15;21(6):1451-64. doi: 10.1016/j.bmc.2012.10.029. Epub 2012 Oct 29.

PMID:
23168081
13.

Synthesis of chromeno[3,4-b]indoles as Lamellarin D analogues: a novel DYRK1A inhibitor class.

Neagoie C, Vedrenne E, Buron F, Mérour JY, Rosca S, Bourg S, Lozach O, Meijer L, Baldeyrou B, Lansiaux A, Routier S.

Eur J Med Chem. 2012 Mar;49:379-96. doi: 10.1016/j.ejmech.2012.01.040. Epub 2012 Jan 25.

PMID:
22305342
14.

Dual inhibition of MAGL and type II topoisomerase by N-phenylmaleimides as a potential strategy to reduce neuroblastoma cell growth.

Matuszak N, Hamtiaux L, Baldeyroux B, Muccioli GG, Poupaert JH, Lansiaux A, Lambert DM.

Eur J Pharm Sci. 2012 Feb 14;45(3):263-71. doi: 10.1016/j.ejps.2011.11.011. Epub 2011 Nov 23.

PMID:
22127371
15.

[Antimetabolites].

Lansiaux A.

Bull Cancer. 2011 Nov;98(11):1263-74. doi: 10.1684/bdc.2011.1476. Review. French.

16.

[Molecular determinants of response to topoisomerase I inhibitors].

Pourquier P, Lansiaux A.

Bull Cancer. 2011 Nov;98(11):1287-98. doi: 10.1684/bdc.2011.1474. Review. French.

17.

[Molecular determinants of response to topoisomerase II inhibitors].

Lansiaux A, Pourquier P.

Bull Cancer. 2011 Nov;98(11):1299-310. doi: 10.1684/bdc.2011.1475. French.

18.

[The inhibitor of integrins Cilengitide: a new active drug in neuro-oncology].

Leblond P, Meignan S, Le Tinier F, Bethe U, Lansiaux A.

Bull Cancer. 2011 Oct;98(9):1083-90. doi: 10.1684/bdc.2011.1429. French.

19.

Synthesis, cytotoxicity and topoisomerase inhibition properties of multifarious aminoalkylated indeno[1,2-c]isoquinolin-5,11-diones.

Ahn G, Schifano-Faux N, Goossens JF, Baldeyrou B, Couture A, Grandclaudon P, Lansiaux A, Ryckebusch A.

Bioorg Med Chem Lett. 2011 Apr 15;21(8):2259-63. doi: 10.1016/j.bmcl.2011.02.106. Epub 2011 Mar 1.

PMID:
21439821
20.

Mechanisms underlying resistance to cetuximab in the HNSCC cell line: role of AKT inhibition in bypassing this resistance.

Rebucci M, Peixoto P, Dewitte A, Wattez N, De Nuncques MA, Rezvoy N, Vautravers-Dewas C, Buisine MP, Guerin E, Peyrat JP, Lartigau E, Lansiaux A.

Int J Oncol. 2011 Jan;38(1):189-200.

PMID:
21109940
21.

Design, synthesis, and DNA-binding of N-alkyl(anilino)quinazoline derivatives.

Garofalo A, Goossens L, Baldeyrou B, Lemoine A, Ravez S, Six P, David-Cordonnier MH, Bonte JP, Depreux P, Lansiaux A, Goossens JF.

J Med Chem. 2010 Nov 25;53(22):8089-103. doi: 10.1021/jm1009605. Epub 2010 Oct 29.

PMID:
21033670
22.

Indeno[1,2-c]isoquinolin-5,11-diones conjugated to amino acids: Synthesis, cytotoxicity, DNA interaction, and topoisomerase II inhibition properties.

Ahn G, Lansiaux A, Goossens JF, Bailly C, Baldeyrou B, Schifano-Faux N, Grandclaudon P, Couture A, Ryckebusch A.

Bioorg Med Chem. 2010 Nov 15;18(22):8119-33. doi: 10.1016/j.bmc.2010.08.025. Epub 2010 Aug 16.

PMID:
20961767
23.

Synthesis and biological activities of new furo[3,4-b]carbazoles: potential topoisomerase II inhibitors.

Hajbi Y, Neagoie C, Biannic B, Chilloux A, Vedrenne E, Baldeyrou B, Bailly C, Mérour JY, Rosca S, Routier S, Lansiaux A.

Eur J Med Chem. 2010 Nov;45(11):5428-37. doi: 10.1016/j.ejmech.2010.09.003. Epub 2010 Sep 15.

PMID:
20863598
24.

Factors for hematopoietic toxicity of carboplatin: refining the targeting of carboplatin systemic exposure.

Schmitt A, Gladieff L, Laffont CM, Evrard A, Boyer JC, Lansiaux A, Bobin-Dubigeon C, Etienne-Grimaldi MC, Boisdron-Celle M, Mousseau M, Pinguet F, Floquet A, Billaud EM, Durdux C, Le Guellec C, Mazières J, Lafont T, Ollivier F, Concordet D, Chatelut E.

J Clin Oncol. 2010 Oct 20;28(30):4568-74. doi: 10.1200/JCO.2010.29.3597. Epub 2010 Sep 20.

PMID:
20855828
25.

Synthesis and biological evaluation of new penta- and heptacyclic indolo- and quinolinocarbazole ring systems obtained via Pd(0) catalysed reductive N-heteroannulation.

Laronze-Cochard M, Cochard F, Daras E, Lansiaux A, Brassart B, Vanquelef E, Prost E, Nuzillard JM, Baldeyrou B, Goosens JF, Lozach O, Meijer L, Riou JF, Henon E, Sapi J.

Org Biomol Chem. 2010 Oct 21;8(20):4625-36. doi: 10.1039/c0ob00149j. Epub 2010 Aug 24.

PMID:
20734015
26.

Montmorillonite K-10 catalyzed cyclization of N-ethoxycarbonyl-N'-arylguanidines: access to pyrimido[4,5-c]carbazole and pyrimido[5,4-b]indole derivatives.

Debray J, Zeghida W, Baldeyrou B, Mahieu C, Lansiaux A, Demeunynck M.

Bioorg Med Chem Lett. 2010 Jul 15;20(14):4244-7. doi: 10.1016/j.bmcl.2010.05.028. Epub 2010 May 31.

PMID:
20570510
27.

Differential apoptosis-like cell death in amastigote and trypomastigote forms from Trypanosoma cruzi-infected heart cells in vitro.

De Souza EM, Nefertiti AS, Bailly C, Lansiaux A, Soeiro MN.

Cell Tissue Res. 2010 Jul;341(1):173-80. doi: 10.1007/s00441-010-0985-5. Epub 2010 May 22.

PMID:
20495825
28.

Circulating thrombospondin 1 level as a surrogate marker in patients receiving cyclophosphamide-based metronomic chemotherapy.

Lansiaux A, Salingue S, Dewitte A, Clisant S, Penel N.

Invest New Drugs. 2012 Feb;30(1):403-4. doi: 10.1007/s10637-010-9443-1. Epub 2010 May 7.

PMID:
20449626
29.

Justification of the starting dose as the main determinant of accrual time in dose-seeking oncology phase 1 trials.

Penel N, Leblond P, Lansiaux A, Clisant S, Dansin E, Adenis A, Bonneterre J.

Invest New Drugs. 2010 Dec;28(6):839-43. doi: 10.1007/s10637-009-9317-6. Epub 2009 Sep 16.

PMID:
19756372
30.

Unusual cellular uptake of cytotoxic 4-hydroxymethyl-3-aminoacridine.

Peixoto P, Zeghida W, Carrez D, Wu TD, Wattez N, Croisy A, Demeunynck M, Guerquin-Kern JL, Lansiaux A.

Eur J Med Chem. 2009 Nov;44(11):4758-63. doi: 10.1016/j.ejmech.2009.06.034. Epub 2009 Jul 4.

PMID:
19640614
31.

Synthesis and antitumoral activity of novel thiazolobenzotriazole, thiazoloindolo[3,2-c]quinoline and quinolinoquinoline derivatives.

Beauchard A, Jaunet A, Murillo L, Baldeyrou B, Lansiaux A, Chérouvrier JR, Domon L, Picot L, Bailly C, Besson T, Thiéry V.

Eur J Med Chem. 2009 Oct;44(10):3858-65. doi: 10.1016/j.ejmech.2009.04.012. Epub 2009 Apr 14.

PMID:
19427714
32.

A universal formula based on cystatin C to perform individual dosing of carboplatin in normal weight, underweight, and obese patients.

Schmitt A, Gladieff L, Lansiaux A, Bobin-Dubigeon C, Etienne-Grimaldi MC, Boisdron-Celle M, Serre-Debauvais F, Pinguet F, Floquet A, Billaud E, Le Guellec C, Penel N, Campone M, Largillier R, Capitain O, Fabbro M, Houede N, Medioni J, Bougnoux P, Lochon I, Chatelut E.

Clin Cancer Res. 2009 May 15;15(10):3633-9. doi: 10.1158/1078-0432.CCR-09-0017. Epub 2009 Apr 28.

33.

Optimized synthesis and enhanced efficacy of novel triplex-forming camptothecin derivatives based on gimatecan.

Vekhoff P, Halby L, Oussedik K, Dallavalle S, Merlini L, Mahieu C, Lansiaux A, Bailly C, Boutorine A, Pisano C, Giannini G, Alloatti D, Arimondo PB.

Bioconjug Chem. 2009 Apr;20(4):666-72. doi: 10.1021/bc800494y.

PMID:
19309124
34.

Synthesis, cytotoxic activity, and DNA binding properties of antitumor cis-1,2-dihydroxy-1,2-dihydrobenzo[b]acronycine cinnamoyl esters.

Do Q, Tian W, Yougnia R, Gaslonde T, Pfeiffer B, Pierré A, Léonce S, Kraus-Berthier L, David-Cordonnier MH, Depauw S, Lansiaux A, Mazinghien R, Koch M, Tillequin F, Michel S, Dufat H.

Bioorg Med Chem. 2009 Mar 1;17(5):1918-27. doi: 10.1016/j.bmc.2009.01.062. Epub 2009 Jan 31.

PMID:
19217791
35.

F14512, a potent antitumor agent targeting topoisomerase II vectored into cancer cells via the polyamine transport system.

Barret JM, Kruczynski A, Vispé S, Annereau JP, Brel V, Guminski Y, Delcros JG, Lansiaux A, Guilbaud N, Imbert T, Bailly C.

Cancer Res. 2008 Dec 1;68(23):9845-53. doi: 10.1158/0008-5472.CAN-08-2748.

36.

Synthesis and biological evaluation of novel oxophenylarcyriaflavins as potential anticancer agents.

Bourderioux A, Bénéteau V, Mérour JY, Baldeyrou B, Ballot C, Lansiaux A, Bailly C, Le Guével R, Guillouzo C, Routier S.

Org Biomol Chem. 2008 Jun 21;6(12):2108-17. doi: 10.1039/b801121d. Epub 2008 Apr 15.

PMID:
18528573
37.

Synthesis, cytotoxicity, DNA interaction, and topoisomerase II inhibition properties of novel indeno[2,1-c]quinolin-7-one and indeno[1,2-c]isoquinolin-5,11-dione derivatives.

Ryckebusch A, Garcin D, Lansiaux A, Goossens JF, Baldeyrou B, Houssin R, Bailly C, Hénichart JP.

J Med Chem. 2008 Jun 26;51(12):3617-29. doi: 10.1021/jm800017u. Epub 2008 May 29.

PMID:
18507368
38.

Synthesis of 3,5-bis(2-indolyl)pyridine and 3-[(2-indolyl)-5-phenyl]pyridine derivatives as CDK inhibitors and cytotoxic agents.

Jacquemard U, Dias N, Lansiaux A, Bailly C, Logé C, Robert JM, Lozach O, Meijer L, Mérour JY, Routier S.

Bioorg Med Chem. 2008 May 1;16(9):4932-53. doi: 10.1016/j.bmc.2008.03.034. Epub 2008 Mar 17.

PMID:
18439832
39.

[Methodological approaches of clinical studies with targeted therapies].

Penel N, Saleron J, Lansiaux A, Clisant S, Adenis A, Fournier C, Duhamel A, Bonneterre J.

Bull Cancer. 2008 Feb;95(2):185-90. doi: 10.1684/bdc.2008.0575. Review. French.

40.

Angiosarcomas and taxanes.

Penel N, Lansiaux A, Adenis A.

Curr Treat Options Oncol. 2007 Dec;8(6):428-34. Epub 2007 Dec 8. Review.

PMID:
18066504
41.

Design of DNA minor groove binding diamidines that recognize GC base pair sequences: a dimeric-hinge interaction motif.

Munde M, Ismail MA, Arafa R, Peixoto P, Collar CJ, Liu Y, Hu L, David-Cordonnier MH, Lansiaux A, Bailly C, Boykin DW, Wilson WD.

J Am Chem Soc. 2007 Nov 7;129(44):13732-43. Epub 2007 Oct 13.

42.

[Pemetrexed: from preclinic to clinic].

Lansiaux A, Lokiec F.

Bull Cancer. 2007;94 Spec No Actualites:S134-8. Review. French.

PMID:
17845983
43.

[Gemcitabine: from preclinic to clinic passing by pharmacokinetics].

Lokiec F, Lansiaux A.

Bull Cancer. 2007;94 Spec No Actualites:S85-9. Review. French.

PMID:
17845976
44.

Novel stable camptothecin derivatives replacing the E-ring lactone by a ketone function are potent inhibitors of topoisomerase I and promising antitumor drugs.

Lansiaux A, Léonce S, Kraus-Berthier L, Bal-Mahieu C, Mazinghien R, Didier S, David-Cordonnier MH, Hautefaye P, Lavielle G, Bailly C, Hickman JA, Pierré A.

Mol Pharmacol. 2007 Aug;72(2):311-9. Epub 2007 May 9.

PMID:
17494837
45.

Design, synthesis and biological evaluation of new oligopyrrole carboxamides linked with tricyclic DNA-intercalators as potential DNA ligands or topoisomerase inhibitors.

David-Cordonnier MH, Hildebrand MP, Baldeyrou B, Lansiaux A, Keuser C, Benzschawel K, Lemster T, Pindur U.

Eur J Med Chem. 2007 Jun;42(6):752-71. Epub 2007 Mar 2.

PMID:
17433851
46.

Chiral capillary electrophoretic determination of the enantiomeric purity of homocamptothecin derivatives, promising antitumor topoisomerase I inhibitors, using highly sulfated CDs and fluorescence detection.

Goossens JF, Mahieu C, Dias N, Bailly C, Principe P, Bonte JP, Lansiaux A, Vaccher C, Foulon C.

Electrophoresis. 2006 Dec;27(23):4717-29.

PMID:
17091464
47.

Amino- and glycoconjugates of pyrido[4,3,2-kl]acridine. Synthesis, antitumor activity, and DNA binding.

Bouffier L, Baldeyrou B, Hildebrand MP, Lansiaux A, David-Cordonnier MH, Carrez D, Croisy A, Renaudet O, Dumy P, Demeunynck M.

Bioorg Med Chem. 2006 Nov 15;14(22):7520-30. Epub 2006 Aug 1.

PMID:
16879973
48.

Generation of replication-dependent double-strand breaks by the novel N2-G-alkylator S23906-1.

Léonce S, Kraus-Berthier L, Golsteyn RM, David-Cordonnier MH, Tardy C, Lansiaux A, Poindessous V, Larsen AK, Pierré A.

Cancer Res. 2006 Jul 15;66(14):7203-10.

49.

Synthesis, antitumor activity, and mechanism of action of benzo[a]pyrano[3,2-h]acridin-7-one analogues of acronycine.

Nguyen TM, Sittisombut C, Boutefnouchet S, Lallemand MC, Michel S, Koch M, Tillequin F, Mazinghien R, Lansiaux A, David-Cordonnier MH, Pfeiffer B, Kraus-Berthier L, Léonce S, Pierré A.

J Med Chem. 2006 Jun 1;49(11):3383-94.

PMID:
16722658
50.

[Histone-deacetylases inhibitors: from TSA to SAHA].

Peixoto P, Lansiaux A.

Bull Cancer. 2006 Jan;93(1):27-36. Review. French.

Supplemental Content

Loading ...
Support Center